Laham-Karam Nihay, Pinto Gaspar P, Poso Antti, Kokkonen Piia
A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
International Clinical Research Center, St. Anne University Hospital, Brno, Czechia.
Front Chem. 2020 Apr 21;8:276. doi: 10.3389/fchem.2020.00276. eCollection 2020.
Transcription and translation are fundamental cellular processes that govern the protein production of cells. These processes are generally up regulated in cancer cells, to maintain the enhanced metabolism and proliferative state of these cells. As such cancerous cells can be susceptible to transcription and translation inhibitors. There are numerous druggable proteins involved in transcription and translation which make lucrative targets for cancer drug development. In addition to proteins, recent years have shown that the "undruggable" transcription factors and RNA molecules can also be targeted to hamper the transcription or translation in cancer. In this review, we summarize the properties and function of the transcription and translation inhibitors that have been tested and developed, focusing on the advances of the last 5 years. To complement this, we also discuss some of the recent advances in targeting oncogenes tightly controlling transcription including transcription factors and KRAS. In addition to natural and synthetic compounds, we review DNA and RNA based approaches to develop cancer drugs. Finally, we conclude with the outlook to the future of the development of transcription and translation inhibitors.
转录和翻译是控制细胞蛋白质产生的基本细胞过程。这些过程在癌细胞中通常会上调,以维持这些细胞增强的代谢和增殖状态。因此,癌细胞可能对转录和翻译抑制剂敏感。有许多参与转录和翻译的可成药蛋白,它们是癌症药物开发的有利可图的靶点。除了蛋白质,近年来还表明,“不可成药”的转录因子和RNA分子也可以成为阻碍癌症转录或翻译的靶点。在这篇综述中,我们总结了已测试和开发的转录和翻译抑制剂的特性和功能,重点关注过去5年的进展。作为补充,我们还讨论了靶向紧密控制转录的癌基因(包括转录因子和KRAS)的一些最新进展。除了天然和合成化合物,我们还综述了基于DNA和RNA的癌症药物开发方法。最后,我们对转录和翻译抑制剂的未来发展前景进行了总结。